HEALIOS K.K. Logo

HEALIOS K.K.

Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.

4593 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
千代田区有楽町一丁目7番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Healios K.K. is a biotechnology company specializing in the research, development, and manufacturing of cell therapy and regenerative medicine products. A pioneer in the field, the company develops treatments for diseases with high unmet medical needs by leveraging induced pluripotent stem (iPS) cell technology and somatic stem cells. Its core R&D focuses on creating therapies from iPS cell-derived products, including retinal pigment epithelium (RPE) cells and Natural Killer (NK) cells for cancer immunotherapy. The company's pipeline also features somatic stem cell products like HLCM051 (MultiStem) for treating conditions such as acute respiratory distress syndrome (ARDS). Healios utilizes proprietary gene editing technology to develop next-generation universal donor cells, aiming to overcome immune rejection and broaden the application of cellular medicine.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HEALIOS K.K. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-13 05:35
Regulatory News Service
確認書
Japanese 8.2 KB
2025-08-13 05:34
Interim Report
半期報告書-第15期(2025/01/01-2025/12/31)
Japanese 436.9 KB
2025-05-13 08:33
Regulatory News Service
臨時報告書
Japanese 19.7 KB
2025-03-27 07:22
Regulatory News Service
臨時報告書
Japanese 25.4 KB
2025-03-27 07:21
Regulatory News Service
確認書
Japanese 8.1 KB
2025-03-27 07:20
Regulatory News Service
内部統制報告書-第14期(2024/01/01-2024/12/31)
Japanese 21.7 KB
2025-03-27 07:19
Annual Report
有価証券報告書-第14期(2024/01/01-2024/12/31)
Japanese 2.0 MB
2025-02-14 05:13
Regulatory News Service
訂正臨時報告書
Japanese 37.5 KB
2025-02-14 04:07
Regulatory News Service
臨時報告書
Japanese 21.3 KB
2025-01-27 07:31
Prospectus
有価証券届出書(参照方式)
Japanese 224.3 KB
2025-01-22 07:33
Regulatory News Service
臨時報告書
Japanese 53.3 KB
2024-11-13 07:34
Regulatory News Service
臨時報告書
Japanese 20.0 KB
2024-08-13 08:04
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2024-08-13 08:04
Regulatory News Service
確認書
Japanese 8.2 KB
2024-08-13 08:03
Interim Report
半期報告書-第14期(2024/01/01-2024/12/31)
Japanese 402.0 KB

Automate Your Workflow. Get a real-time feed of all HEALIOS K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HEALIOS K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
TMS Co., Ltd Logo
Develops small molecule drugs from natural compounds for the global pharmaceutical market.
Japan 4891
Together Pharma Ltd. Logo
Researches and produces medical cannabis products for domestic and European patients.
Israel TGTR
A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.
Japan 4551
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan 4553
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan 4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye TRILC
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium UCB
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong N/A
Univo Pharmaceuticals Ltd. Logo
Vertically integrated biopharma firm developing medical cannabis treatments with a focus on CNS.
Israel UNVO-M
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France ALVAL

Talk to a Data Expert

Have a question? We'll get back to you promptly.